In acute COVID-19, the retained intron isoform 202 of LEF1-AS1 was identified as a potential biomarker for both the outcome and severity of the disease [24,25], displaying lower levels in more severe and non-surviving COVID-19 patients. The gene discussed is LEF1; the disease is COVID-19.